Earlier this week, IBA's joint venture PanTera secured € 93m in an oversubscribed Series A funding round, making it the largest in Belgian life science history. The post money valuation of € 280m implies a valuation of IBA's stake of € 88m or € 2.9ps, or comfortably above the previous book value of € 0.6ps. Incorporating this into our model, we increased our TP from € 16.0 to € 18.0 per share on Wednesday and reiterated our Buy rating. In this note, we take a closer look at the strong growth dri...
We updated our model as in 2Q24 Materialise continued on its growth path, generating record-high quarterly revenues with all three of its business segments reporting increased revenues. Especially the Medical segment turned in another strong performance, growing by 13%, while also its Software and Manufacturing segments posted higher revenues. We also welcome that -in another step forward- Materialise acquired begin 2H24 FEops, a Belgian company that develops AI-driven simulation technology to i...
NAV rose by 3% €482.0m or €13.26ps (vs. €468.0m during FY23-end). Portfolio result came in at €21.9m (9.4% annualised) while net result clocked in at €18.0m or €0.5 per share. Shareholder's equity declined slightly to €482.0m compared to €494.6m during FY23-end – this is after deducting the dividend of €30.5m (€0.84ps) paid in May'24. Total cash receipts generated by the portfolio during 1H amounted to €23.1m while TINC committed €50.2m towards 3 new projects. Currently, TINC has a net debt pos...
This morning, IBA announced that Pantera secured € 93m in an oversubscribed series A round (the largest in Belgian life science history), valuing Pantera at € 280m post money valuation. Additionally, IBA and SFPIM will convert € 7.2m in convertible loans, while € 33.8m in debt has also been secured, bringing the total amount raised to € 134m. Following the transaction, IBA's will hold a 31.3% stake in Pantera, compared to 47.8% previously. The funds will be used primarily to support the construc...
1M Performance - Absolute: During July'24 (1M period), the KBCS Holdings Universe posted a return of 0.5% which was mainly driven by multi-asset holdings (+1.7%) while single-asset holdings posted a negative return of -1.3%. The 3 top performers during the period were HAL Trust (+5.1%), Texaf (+2.9%), and The Infrastructure Company (TINC, +9.6%) while the 3 worst performers were Brederode (-2.8%), Solvac (-5.3%), and Whitestone Group (-7.2%). YTD Performance - Relative: On a YTD basis (as of A...
IBA’s joint venture PanTera secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 production Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is focussed on the production of actinium-225, a novel radioisotope used in a new class of targeted treatments for cancer. The Series A financing values PanTera at about EUR 280 million post money. Prior to the funding round, IBA had a 47.8% sharehold...
PanTera, la joint-venture d’IBA, obtient 93 millions d'euros lors d'une levée de fonds de série A sursouscrite pour accélérer la production mondiale d'actinium-225 Louvain-La-Neuve, Belgique, le 11 septembre 2024 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’accélération de particules, partage aujourd’hui le communiqué de presse ci-dessous concernant sa joint-venture PanTera qui a pour objectif d’assurer la production à grande échelle d'actinium-225, un radioisotope novateur utilisé dans une nouvelle classe de traitements ciblés contre le cancer. La levée de fon...
In this September update of our Dynamic Top Pick List we make 4 changes. •We include Cofinimmo in our Dynamic Top Pick List after our recent upgrade from Accumulate to Buy. We expect the name to outperform in a decreasing interest rate environment given its relatively high leverage and cheap valuation. We also believe the risk of a dilutive equity raise eased when the FY24 capex decreased from € 320m to € 250m. The management stays disciplined in its capex program and continues to focus on asse...
IBA Reports Half Year 2024 Results GROUP REVENUES UP 21.9% ACCELERATED BACKLOG CONVERSION IN PROTON THERAPY AND OTHER ACCELERATORS STRONG GROSS MARGIN IMPROVEMENT AND BREAKEVEN REBIT Louvain-la-Neuve, Belgium, 29 August 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2024. (EUR 000)H1 2024H1 2023VarianceVariance %Total Revenues206 452169 41837 03421.9% Proton Therapy107 72495 08212 64213.3% Other Accelerators70 07841 35428 72469.5% Dosimetry28 64932 982-4 333-13...
IBA publie ses résultats du premier semestre 2024 REVENUS DU GROUPE EN HAUSSE DE 21,9% ACCELERATION DE LA CONVERSION DU CARNET DE COMMANDES EN PROTONTHÉRAPIE ET AUTRES ACCELERATEURS FORTE AMELIORATION DE LA MARGE BRUTE ET REBIT À L’EQUILIBRE Louvain-La-Neuve, Belgique, jeudi 29 août 2024 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’accélération de particules, annonce ce jour ses résultats consolidés pour le premier semestre 2024. (EUR 000)S1 2024S1 2023VariationVariation %Total Ventes et Prestations206 452169 41837 03421,9%Protonthérapie 107 72495 082...
IBA secures deal with the University of Pennsylvania Health System for two Proteus®ONE proton therapy solutions Agreement further strengthens the long-term relationship between IBA and the University of Pennsylvania Louvain-La-Neuve, Belgium, August 27, 2024 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a Memorandum of Understanding with the University of Pennsylvania Health System for the installation of two Proteus®ONE1 c...
IBA conclut un accord avec University of Pennsylvania Health System pour deux solutions de protonthérapie Proteus®ONE Un accord dans la continuité du partenariat à long terme entre IBA et University of Pennsylvania Louvain-la-Neuve, Belgique, le 27 août 2024 - IBA (Ion Beam Applications S.A., EURONEXT) le leader mondial des technologies d’accélération de particules et le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui avoir signé un Protocole d'Accord avec University of Pennsylvania Health System pour l'installation de deux solut...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.